nodes	percent_of_prediction	percent_of_DWPC	metapath
Tadalafil—CYP3A4—breast cancer	0.249	1	CbGaD
Tadalafil—CYP3A4—Exemestane—breast cancer	0.0511	0.133	CbGbCtD
Tadalafil—CYP3A4—Letrozole—breast cancer	0.0435	0.113	CbGbCtD
Tadalafil—CYP3A4—Anastrozole—breast cancer	0.0388	0.101	CbGbCtD
Tadalafil—CYP3A4—Toremifene—breast cancer	0.0355	0.0921	CbGbCtD
Tadalafil—CYP3A4—Fulvestrant—breast cancer	0.033	0.0856	CbGbCtD
Tadalafil—CYP3A4—Thiotepa—breast cancer	0.0294	0.0763	CbGbCtD
Tadalafil—CYP3A4—Ixabepilone—breast cancer	0.0269	0.0698	CbGbCtD
Tadalafil—CYP3A4—Lapatinib—breast cancer	0.0259	0.0672	CbGbCtD
Tadalafil—CYP3A4—Raloxifene—breast cancer	0.0196	0.0509	CbGbCtD
Tadalafil—CYP3A4—Vinorelbine—breast cancer	0.0143	0.0373	CbGbCtD
Tadalafil—CYP3A4—Tamoxifen—breast cancer	0.013	0.0336	CbGbCtD
Tadalafil—CYP3A4—Mitoxantrone—breast cancer	0.0126	0.0328	CbGbCtD
Tadalafil—CYP3A4—Paclitaxel—breast cancer	0.0101	0.0262	CbGbCtD
Tadalafil—CYP3A4—Irinotecan—breast cancer	0.00994	0.0258	CbGbCtD
Tadalafil—CYP3A4—Vinblastine—breast cancer	0.00884	0.023	CbGbCtD
Tadalafil—CYP3A4—Docetaxel—breast cancer	0.00729	0.0189	CbGbCtD
Tadalafil—CYP3A4—Doxorubicin—breast cancer	0.00543	0.0141	CbGbCtD
Tadalafil—PDE11A—epithelium—breast cancer	0.00336	0.226	CbGeAlD
Tadalafil—PDE11A—adrenal gland—breast cancer	0.00243	0.164	CbGeAlD
Tadalafil—PDE11A—endocrine gland—breast cancer	0.00211	0.142	CbGeAlD
Tadalafil—PDE5A—epithelium—breast cancer	0.00128	0.086	CbGeAlD
Tadalafil—PDE5A—adipose tissue—breast cancer	0.00103	0.0695	CbGeAlD
Tadalafil—PDE5A—female reproductive system—breast cancer	0.000949	0.0639	CbGeAlD
Tadalafil—PDE5A—adrenal gland—breast cancer	0.000926	0.0623	CbGeAlD
Tadalafil—PDE5A—female gonad—breast cancer	0.000863	0.0581	CbGeAlD
Tadalafil—PDE5A—endocrine gland—breast cancer	0.000803	0.0541	CbGeAlD
Tadalafil—PDE5A—lymph node—breast cancer	0.000555	0.0374	CbGeAlD
Tadalafil—CYP3A4—female reproductive system—breast cancer	0.000296	0.0199	CbGeAlD
Tadalafil—CYP3A4—endocrine gland—breast cancer	0.00025	0.0169	CbGeAlD
Tadalafil—PDE11A—Signaling Pathways—JAG1—breast cancer	5.68e-05	0.000541	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PARP1—breast cancer	5.65e-05	0.000539	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NOTCH3—breast cancer	5.65e-05	0.000539	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CALCA—breast cancer	5.59e-05	0.000532	CbGpPWpGaD
Tadalafil—Skin disorder—Capecitabine—breast cancer	5.57e-05	0.000226	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—SRC—breast cancer	5.56e-05	0.00053	CbGpPWpGaD
Tadalafil—Sweating—Doxorubicin—breast cancer	5.55e-05	0.000226	CcSEcCtD
Tadalafil—Urinary tract disorder—Epirubicin—breast cancer	5.55e-05	0.000225	CcSEcCtD
Tadalafil—Urticaria—Paclitaxel—breast cancer	5.55e-05	0.000225	CcSEcCtD
Tadalafil—Hyperhidrosis—Capecitabine—breast cancer	5.54e-05	0.000225	CcSEcCtD
Tadalafil—Oedema peripheral—Epirubicin—breast cancer	5.54e-05	0.000225	CcSEcCtD
Tadalafil—Hypotension—Docetaxel—breast cancer	5.53e-05	0.000225	CcSEcCtD
Tadalafil—Haematuria—Doxorubicin—breast cancer	5.52e-05	0.000224	CcSEcCtD
Tadalafil—Connective tissue disorder—Epirubicin—breast cancer	5.52e-05	0.000224	CcSEcCtD
Tadalafil—Abdominal pain—Paclitaxel—breast cancer	5.52e-05	0.000224	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—RPS6—breast cancer	5.52e-05	0.000526	CbGpPWpGaD
Tadalafil—Urethral disorder—Epirubicin—breast cancer	5.51e-05	0.000224	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—FGF4—breast cancer	5.48e-05	0.000522	CbGpPWpGaD
Tadalafil—Epistaxis—Doxorubicin—breast cancer	5.46e-05	0.000222	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CXCR4—breast cancer	5.46e-05	0.00052	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CXCL12—breast cancer	5.46e-05	0.00052	CbGpPWpGaD
Tadalafil—Angiopathy—Methotrexate—breast cancer	5.45e-05	0.000221	CcSEcCtD
Tadalafil—Vomiting—Mitoxantrone—breast cancer	5.45e-05	0.000221	CcSEcCtD
Tadalafil—Vomiting—Irinotecan—breast cancer	5.45e-05	0.000221	CcSEcCtD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—breast cancer	5.43e-05	0.000518	CbGpPWpGaD
Tadalafil—Immune system disorder—Methotrexate—breast cancer	5.43e-05	0.00022	CcSEcCtD
Tadalafil—Dizziness—Fluorouracil—breast cancer	5.42e-05	0.00022	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—VEGFA—breast cancer	5.42e-05	0.000516	CbGpPWpGaD
Tadalafil—Mediastinal disorder—Methotrexate—breast cancer	5.41e-05	0.00022	CcSEcCtD
Tadalafil—Rash—Irinotecan—breast cancer	5.4e-05	0.000219	CcSEcCtD
Tadalafil—Rash—Mitoxantrone—breast cancer	5.4e-05	0.000219	CcSEcCtD
Tadalafil—Dermatitis—Irinotecan—breast cancer	5.4e-05	0.000219	CcSEcCtD
Tadalafil—Dermatitis—Mitoxantrone—breast cancer	5.4e-05	0.000219	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Docetaxel—breast cancer	5.39e-05	0.000219	CcSEcCtD
Tadalafil—Headache—Irinotecan—breast cancer	5.37e-05	0.000218	CcSEcCtD
Tadalafil—Headache—Mitoxantrone—breast cancer	5.37e-05	0.000218	CcSEcCtD
Tadalafil—Hypotension—Capecitabine—breast cancer	5.36e-05	0.000218	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PAK1—breast cancer	5.36e-05	0.00051	CbGpPWpGaD
Tadalafil—Insomnia—Docetaxel—breast cancer	5.35e-05	0.000217	CcSEcCtD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—breast cancer	5.35e-05	0.00051	CbGpPWpGaD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—breast cancer	5.32e-05	0.000507	CbGpPWpGaD
Tadalafil—Paraesthesia—Docetaxel—breast cancer	5.32e-05	0.000216	CcSEcCtD
Tadalafil—Erythema multiforme—Epirubicin—breast cancer	5.31e-05	0.000216	CcSEcCtD
Tadalafil—Vomiting—Gemcitabine—breast cancer	5.3e-05	0.000215	CcSEcCtD
Tadalafil—Dyspnoea—Docetaxel—breast cancer	5.28e-05	0.000214	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—GSTA4—breast cancer	5.27e-05	0.000502	CbGpPWpGaD
Tadalafil—Somnolence—Docetaxel—breast cancer	5.26e-05	0.000214	CcSEcCtD
Tadalafil—Mental disorder—Methotrexate—breast cancer	5.26e-05	0.000214	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—TCF7L2—breast cancer	5.26e-05	0.000501	CbGpPWpGaD
Tadalafil—Rash—Gemcitabine—breast cancer	5.26e-05	0.000214	CcSEcCtD
Tadalafil—Dermatitis—Gemcitabine—breast cancer	5.26e-05	0.000213	CcSEcCtD
Tadalafil—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—breast cancer	5.25e-05	0.000501	CbGpPWpGaD
Tadalafil—Eye disorder—Epirubicin—breast cancer	5.25e-05	0.000213	CcSEcCtD
Tadalafil—Tinnitus—Epirubicin—breast cancer	5.24e-05	0.000213	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—AKT2—breast cancer	5.24e-05	0.000499	CbGpPWpGaD
Tadalafil—Haemoglobin—Doxorubicin—breast cancer	5.23e-05	0.000212	CcSEcCtD
Tadalafil—Headache—Gemcitabine—breast cancer	5.23e-05	0.000212	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Capecitabine—breast cancer	5.22e-05	0.000212	CcSEcCtD
Tadalafil—Flushing—Epirubicin—breast cancer	5.22e-05	0.000212	CcSEcCtD
Tadalafil—Cardiac disorder—Epirubicin—breast cancer	5.22e-05	0.000212	CcSEcCtD
Tadalafil—Vomiting—Fluorouracil—breast cancer	5.22e-05	0.000212	CcSEcCtD
Tadalafil—Rhinitis—Doxorubicin—breast cancer	5.21e-05	0.000212	CcSEcCtD
Tadalafil—Dyspepsia—Docetaxel—breast cancer	5.21e-05	0.000212	CcSEcCtD
Tadalafil—Haemorrhage—Doxorubicin—breast cancer	5.2e-05	0.000211	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CG—breast cancer	5.2e-05	0.000495	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTA4—breast cancer	5.19e-05	0.000495	CbGpPWpGaD
Tadalafil—Insomnia—Capecitabine—breast cancer	5.18e-05	0.000211	CcSEcCtD
Tadalafil—Hypoaesthesia—Doxorubicin—breast cancer	5.17e-05	0.00021	CcSEcCtD
Tadalafil—Rash—Fluorouracil—breast cancer	5.17e-05	0.00021	CcSEcCtD
Tadalafil—Dermatitis—Fluorouracil—breast cancer	5.17e-05	0.00021	CcSEcCtD
Tadalafil—Pharyngitis—Doxorubicin—breast cancer	5.16e-05	0.00021	CcSEcCtD
Tadalafil—Paraesthesia—Capecitabine—breast cancer	5.15e-05	0.000209	CcSEcCtD
Tadalafil—Hypersensitivity—Paclitaxel—breast cancer	5.15e-05	0.000209	CcSEcCtD
Tadalafil—Headache—Fluorouracil—breast cancer	5.14e-05	0.000209	CcSEcCtD
Tadalafil—Urinary tract disorder—Doxorubicin—breast cancer	5.14e-05	0.000209	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—GSTA2—breast cancer	5.13e-05	0.000489	CbGpPWpGaD
Tadalafil—Oedema peripheral—Doxorubicin—breast cancer	5.12e-05	0.000208	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—MAPK3—breast cancer	5.12e-05	0.000488	CbGpPWpGaD
Tadalafil—Gastrointestinal disorder—Docetaxel—breast cancer	5.11e-05	0.000208	CcSEcCtD
Tadalafil—Connective tissue disorder—Doxorubicin—breast cancer	5.11e-05	0.000208	CcSEcCtD
Tadalafil—Dyspnoea—Capecitabine—breast cancer	5.11e-05	0.000208	CcSEcCtD
Tadalafil—Fatigue—Docetaxel—breast cancer	5.1e-05	0.000207	CcSEcCtD
Tadalafil—Angiopathy—Epirubicin—breast cancer	5.1e-05	0.000207	CcSEcCtD
Tadalafil—Urethral disorder—Doxorubicin—breast cancer	5.1e-05	0.000207	CcSEcCtD
Tadalafil—Nausea—Irinotecan—breast cancer	5.09e-05	0.000207	CcSEcCtD
Tadalafil—Nausea—Mitoxantrone—breast cancer	5.09e-05	0.000207	CcSEcCtD
Tadalafil—Immune system disorder—Epirubicin—breast cancer	5.08e-05	0.000206	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—NOTCH2—breast cancer	5.07e-05	0.000484	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HSP90AA1—breast cancer	5.07e-05	0.000484	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—SULT1A1—breast cancer	5.07e-05	0.000483	CbGpPWpGaD
Tadalafil—Mediastinal disorder—Epirubicin—breast cancer	5.07e-05	0.000206	CcSEcCtD
Tadalafil—Constipation—Docetaxel—breast cancer	5.06e-05	0.000206	CcSEcCtD
Tadalafil—Pain—Docetaxel—breast cancer	5.06e-05	0.000206	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—GPX2—breast cancer	5.06e-05	0.000482	CbGpPWpGaD
Tadalafil—Back pain—Methotrexate—breast cancer	5.06e-05	0.000205	CcSEcCtD
Tadalafil—Dyspepsia—Capecitabine—breast cancer	5.05e-05	0.000205	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CD—breast cancer	5.03e-05	0.00048	CbGpPWpGaD
Tadalafil—Asthenia—Paclitaxel—breast cancer	5.01e-05	0.000204	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—GPX4—breast cancer	5e-05	0.000477	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—SULT1A1—breast cancer	5e-05	0.000477	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—TGFB1—breast cancer	4.97e-05	0.000474	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—SRC—breast cancer	4.96e-05	0.000472	CbGpPWpGaD
Tadalafil—Nausea—Gemcitabine—breast cancer	4.96e-05	0.000201	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—GSTA1—breast cancer	4.95e-05	0.000472	CbGpPWpGaD
Tadalafil—Gastrointestinal disorder—Capecitabine—breast cancer	4.95e-05	0.000201	CcSEcCtD
Tadalafil—Fatigue—Capecitabine—breast cancer	4.94e-05	0.000201	CcSEcCtD
Tadalafil—Pruritus—Paclitaxel—breast cancer	4.94e-05	0.000201	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PRL—breast cancer	4.93e-05	0.00047	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AGTR1—breast cancer	4.93e-05	0.00047	CbGpPWpGaD
Tadalafil—Vision blurred—Methotrexate—breast cancer	4.93e-05	0.0002	CcSEcCtD
Tadalafil—Mental disorder—Epirubicin—breast cancer	4.92e-05	0.0002	CcSEcCtD
Tadalafil—Erythema multiforme—Doxorubicin—breast cancer	4.92e-05	0.0002	CcSEcCtD
Tadalafil—Constipation—Capecitabine—breast cancer	4.9e-05	0.000199	CcSEcCtD
Tadalafil—Pain—Capecitabine—breast cancer	4.9e-05	0.000199	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—NAT2—breast cancer	4.9e-05	0.000467	CbGpPWpGaD
Tadalafil—Nausea—Fluorouracil—breast cancer	4.87e-05	0.000198	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ADAM10—breast cancer	4.86e-05	0.000464	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—STK11—breast cancer	4.86e-05	0.000464	CbGpPWpGaD
Tadalafil—Eye disorder—Doxorubicin—breast cancer	4.86e-05	0.000197	CcSEcCtD
Tadalafil—Tinnitus—Doxorubicin—breast cancer	4.85e-05	0.000197	CcSEcCtD
Tadalafil—Gastrointestinal pain—Docetaxel—breast cancer	4.84e-05	0.000197	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—NAT2—breast cancer	4.83e-05	0.00046	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—VEGFA—breast cancer	4.83e-05	0.00046	CbGpPWpGaD
Tadalafil—Flushing—Doxorubicin—breast cancer	4.83e-05	0.000196	CcSEcCtD
Tadalafil—Cardiac disorder—Doxorubicin—breast cancer	4.83e-05	0.000196	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PLG—breast cancer	4.81e-05	0.000458	CbGpPWpGaD
Tadalafil—Diarrhoea—Paclitaxel—breast cancer	4.78e-05	0.000194	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—AKT2—breast cancer	4.76e-05	0.000453	CbGpPWpGaD
Tadalafil—Back pain—Epirubicin—breast cancer	4.73e-05	0.000192	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—FGF10—breast cancer	4.73e-05	0.000451	CbGpPWpGaD
Tadalafil—Angiopathy—Doxorubicin—breast cancer	4.72e-05	0.000192	CcSEcCtD
Tadalafil—Muscle spasms—Epirubicin—breast cancer	4.7e-05	0.000191	CcSEcCtD
Tadalafil—Immune system disorder—Doxorubicin—breast cancer	4.7e-05	0.000191	CcSEcCtD
Tadalafil—Vertigo—Methotrexate—breast cancer	4.7e-05	0.000191	CcSEcCtD
Tadalafil—Gastrointestinal pain—Capecitabine—breast cancer	4.69e-05	0.00019	CcSEcCtD
Tadalafil—Mediastinal disorder—Doxorubicin—breast cancer	4.69e-05	0.00019	CcSEcCtD
Tadalafil—Abdominal pain—Docetaxel—breast cancer	4.68e-05	0.00019	CcSEcCtD
Tadalafil—Dizziness—Paclitaxel—breast cancer	4.62e-05	0.000188	CcSEcCtD
Tadalafil—Vision blurred—Epirubicin—breast cancer	4.61e-05	0.000187	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—KRAS—breast cancer	4.6e-05	0.000439	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CD—breast cancer	4.57e-05	0.000436	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—MAPK3—breast cancer	4.57e-05	0.000435	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PDGFA—breast cancer	4.56e-05	0.000435	CbGpPWpGaD
Tadalafil—Cough—Methotrexate—breast cancer	4.56e-05	0.000185	CcSEcCtD
Tadalafil—Mental disorder—Doxorubicin—breast cancer	4.56e-05	0.000185	CcSEcCtD
Tadalafil—Urticaria—Capecitabine—breast cancer	4.55e-05	0.000185	CcSEcCtD
Tadalafil—Abdominal pain—Capecitabine—breast cancer	4.53e-05	0.000184	CcSEcCtD
Tadalafil—Convulsion—Methotrexate—breast cancer	4.53e-05	0.000184	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—TGFBR2—breast cancer	4.5e-05	0.000429	CbGpPWpGaD
Tadalafil—Arthralgia—Methotrexate—breast cancer	4.45e-05	0.000181	CcSEcCtD
Tadalafil—Myalgia—Methotrexate—breast cancer	4.45e-05	0.000181	CcSEcCtD
Tadalafil—Chest pain—Methotrexate—breast cancer	4.45e-05	0.000181	CcSEcCtD
Tadalafil—Vomiting—Paclitaxel—breast cancer	4.44e-05	0.00018	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—TGFB1—breast cancer	4.43e-05	0.000422	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ITPR1—breast cancer	4.43e-05	0.000422	CbGpPWpGaD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	4.42e-05	0.00018	CcSEcCtD
Tadalafil—Rash—Paclitaxel—breast cancer	4.4e-05	0.000179	CcSEcCtD
Tadalafil—Dermatitis—Paclitaxel—breast cancer	4.4e-05	0.000179	CcSEcCtD
Tadalafil—Discomfort—Methotrexate—breast cancer	4.4e-05	0.000179	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ERBB4—breast cancer	4.4e-05	0.000419	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—STAT5A—breast cancer	4.4e-05	0.000419	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MMP3—breast cancer	4.4e-05	0.000419	CbGpPWpGaD
Tadalafil—Vertigo—Epirubicin—breast cancer	4.4e-05	0.000179	CcSEcCtD
Tadalafil—Syncope—Epirubicin—breast cancer	4.39e-05	0.000178	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CB—breast cancer	4.39e-05	0.000418	CbGpPWpGaD
Tadalafil—Back pain—Doxorubicin—breast cancer	4.38e-05	0.000178	CcSEcCtD
Tadalafil—Headache—Paclitaxel—breast cancer	4.38e-05	0.000178	CcSEcCtD
Tadalafil—Hypersensitivity—Docetaxel—breast cancer	4.36e-05	0.000177	CcSEcCtD
Tadalafil—Muscle spasms—Doxorubicin—breast cancer	4.35e-05	0.000177	CcSEcCtD
Tadalafil—Palpitations—Epirubicin—breast cancer	4.32e-05	0.000176	CcSEcCtD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—breast cancer	4.32e-05	0.000411	CbGpPWpGaD
Tadalafil—Loss of consciousness—Epirubicin—breast cancer	4.3e-05	0.000175	CcSEcCtD
Tadalafil—Cough—Epirubicin—breast cancer	4.27e-05	0.000173	CcSEcCtD
Tadalafil—Vision blurred—Doxorubicin—breast cancer	4.27e-05	0.000173	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—SMAD4—breast cancer	4.26e-05	0.000406	CbGpPWpGaD
Tadalafil—Asthenia—Docetaxel—breast cancer	4.25e-05	0.000173	CcSEcCtD
Tadalafil—Convulsion—Epirubicin—breast cancer	4.24e-05	0.000172	CcSEcCtD
Tadalafil—Infection—Methotrexate—breast cancer	4.24e-05	0.000172	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—IGF1R—breast cancer	4.23e-05	0.000404	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PIK3CA—breast cancer	4.23e-05	0.000403	CbGpPWpGaD
Tadalafil—Hypertension—Epirubicin—breast cancer	4.22e-05	0.000172	CcSEcCtD
Tadalafil—Hypersensitivity—Capecitabine—breast cancer	4.22e-05	0.000172	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—CXCL8—breast cancer	4.21e-05	0.000402	CbGpPWpGaD
Tadalafil—Pruritus—Docetaxel—breast cancer	4.19e-05	0.00017	CcSEcCtD
Tadalafil—Nervous system disorder—Methotrexate—breast cancer	4.18e-05	0.00017	CcSEcCtD
Tadalafil—Arthralgia—Epirubicin—breast cancer	4.17e-05	0.000169	CcSEcCtD
Tadalafil—Myalgia—Epirubicin—breast cancer	4.17e-05	0.000169	CcSEcCtD
Tadalafil—Chest pain—Epirubicin—breast cancer	4.17e-05	0.000169	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—HES1—breast cancer	4.16e-05	0.000396	CbGpPWpGaD
Tadalafil—Nausea—Paclitaxel—breast cancer	4.15e-05	0.000168	CcSEcCtD
Tadalafil—Skin disorder—Methotrexate—breast cancer	4.14e-05	0.000168	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	4.14e-05	0.000168	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PLA2G4A—breast cancer	4.13e-05	0.000394	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NCOR1—breast cancer	4.13e-05	0.000394	CbGpPWpGaD
Tadalafil—Hyperhidrosis—Methotrexate—breast cancer	4.13e-05	0.000168	CcSEcCtD
Tadalafil—Discomfort—Epirubicin—breast cancer	4.12e-05	0.000167	CcSEcCtD
Tadalafil—Asthenia—Capecitabine—breast cancer	4.11e-05	0.000167	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—KRAS—breast cancer	4.1e-05	0.000391	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—TP53—breast cancer	4.09e-05	0.00039	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FGF1—breast cancer	4.09e-05	0.00039	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CSF2—breast cancer	4.09e-05	0.00039	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—RAF1—breast cancer	4.08e-05	0.000389	CbGpPWpGaD
Tadalafil—Dry mouth—Epirubicin—breast cancer	4.07e-05	0.000165	CcSEcCtD
Tadalafil—Vertigo—Doxorubicin—breast cancer	4.07e-05	0.000165	CcSEcCtD
Tadalafil—CYP3A4—Tryptophan metabolism—MDM2—breast cancer	4.06e-05	0.000387	CbGpPWpGaD
Tadalafil—Syncope—Doxorubicin—breast cancer	4.06e-05	0.000165	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—NRG1—breast cancer	4.06e-05	0.000387	CbGpPWpGaD
Tadalafil—Pruritus—Capecitabine—breast cancer	4.06e-05	0.000165	CcSEcCtD
Tadalafil—Diarrhoea—Docetaxel—breast cancer	4.05e-05	0.000165	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—H2AFX—breast cancer	4.03e-05	0.000384	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—IL2—breast cancer	4.03e-05	0.000384	CbGpPWpGaD
Tadalafil—Palpitations—Doxorubicin—breast cancer	4e-05	0.000162	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—E2F1—breast cancer	4e-05	0.000381	CbGpPWpGaD
Tadalafil—Oedema—Epirubicin—breast cancer	3.99e-05	0.000162	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—MTR—breast cancer	3.99e-05	0.00038	CbGpPWpGaD
Tadalafil—Hypotension—Methotrexate—breast cancer	3.99e-05	0.000162	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CB—breast cancer	3.98e-05	0.00038	CbGpPWpGaD
Tadalafil—Loss of consciousness—Doxorubicin—breast cancer	3.98e-05	0.000162	CcSEcCtD
Tadalafil—Infection—Epirubicin—breast cancer	3.97e-05	0.000161	CcSEcCtD
Tadalafil—Cough—Doxorubicin—breast cancer	3.95e-05	0.00016	CcSEcCtD
Tadalafil—Shock—Epirubicin—breast cancer	3.93e-05	0.00016	CcSEcCtD
Tadalafil—Convulsion—Doxorubicin—breast cancer	3.92e-05	0.000159	CcSEcCtD
Tadalafil—Diarrhoea—Capecitabine—breast cancer	3.92e-05	0.000159	CcSEcCtD
Tadalafil—Nervous system disorder—Epirubicin—breast cancer	3.92e-05	0.000159	CcSEcCtD
Tadalafil—Dizziness—Docetaxel—breast cancer	3.92e-05	0.000159	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—HPGDS—breast cancer	3.91e-05	0.000373	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—HRAS—breast cancer	3.91e-05	0.000373	CbGpPWpGaD
Tadalafil—Hypertension—Doxorubicin—breast cancer	3.91e-05	0.000159	CcSEcCtD
Tadalafil—Tachycardia—Epirubicin—breast cancer	3.9e-05	0.000158	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Methotrexate—breast cancer	3.89e-05	0.000158	CcSEcCtD
Tadalafil—Skin disorder—Epirubicin—breast cancer	3.88e-05	0.000158	CcSEcCtD
Tadalafil—Hyperhidrosis—Epirubicin—breast cancer	3.86e-05	0.000157	CcSEcCtD
Tadalafil—Insomnia—Methotrexate—breast cancer	3.86e-05	0.000157	CcSEcCtD
Tadalafil—Chest pain—Doxorubicin—breast cancer	3.85e-05	0.000157	CcSEcCtD
Tadalafil—Arthralgia—Doxorubicin—breast cancer	3.85e-05	0.000157	CcSEcCtD
Tadalafil—Myalgia—Doxorubicin—breast cancer	3.85e-05	0.000157	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—SPP1—breast cancer	3.84e-05	0.000366	CbGpPWpGaD
Tadalafil—Paraesthesia—Methotrexate—breast cancer	3.83e-05	0.000156	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.83e-05	0.000155	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—CXCL8—breast cancer	3.83e-05	0.000365	CbGpPWpGaD
Tadalafil—Discomfort—Doxorubicin—breast cancer	3.81e-05	0.000155	CcSEcCtD
Tadalafil—Dyspnoea—Methotrexate—breast cancer	3.8e-05	0.000154	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ERBB3—breast cancer	3.8e-05	0.000362	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FGFR2—breast cancer	3.8e-05	0.000362	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTT1—breast cancer	3.8e-05	0.000362	CbGpPWpGaD
Tadalafil—Somnolence—Methotrexate—breast cancer	3.79e-05	0.000154	CcSEcCtD
Tadalafil—Dizziness—Capecitabine—breast cancer	3.79e-05	0.000154	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—PIK3CA—breast cancer	3.77e-05	0.000359	CbGpPWpGaD
Tadalafil—Dry mouth—Doxorubicin—breast cancer	3.77e-05	0.000153	CcSEcCtD
Tadalafil—Vomiting—Docetaxel—breast cancer	3.76e-05	0.000153	CcSEcCtD
Tadalafil—Dyspepsia—Methotrexate—breast cancer	3.76e-05	0.000153	CcSEcCtD
Tadalafil—Rash—Docetaxel—breast cancer	3.73e-05	0.000152	CcSEcCtD
Tadalafil—Hypotension—Epirubicin—breast cancer	3.73e-05	0.000152	CcSEcCtD
Tadalafil—Dermatitis—Docetaxel—breast cancer	3.73e-05	0.000151	CcSEcCtD
Tadalafil—Headache—Docetaxel—breast cancer	3.71e-05	0.000151	CcSEcCtD
Tadalafil—Oedema—Doxorubicin—breast cancer	3.7e-05	0.00015	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Methotrexate—breast cancer	3.68e-05	0.00015	CcSEcCtD
Tadalafil—Fatigue—Methotrexate—breast cancer	3.68e-05	0.000149	CcSEcCtD
Tadalafil—Infection—Doxorubicin—breast cancer	3.67e-05	0.000149	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—IL2—breast cancer	3.66e-05	0.000349	CbGpPWpGaD
Tadalafil—Pain—Methotrexate—breast cancer	3.65e-05	0.000148	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—TP53—breast cancer	3.65e-05	0.000348	CbGpPWpGaD
Tadalafil—Vomiting—Capecitabine—breast cancer	3.64e-05	0.000148	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—TERT—breast cancer	3.64e-05	0.000347	CbGpPWpGaD
Tadalafil—Musculoskeletal discomfort—Epirubicin—breast cancer	3.64e-05	0.000148	CcSEcCtD
Tadalafil—Shock—Doxorubicin—breast cancer	3.64e-05	0.000148	CcSEcCtD
Tadalafil—Nervous system disorder—Doxorubicin—breast cancer	3.62e-05	0.000147	CcSEcCtD
Tadalafil—Rash—Capecitabine—breast cancer	3.61e-05	0.000147	CcSEcCtD
Tadalafil—Insomnia—Epirubicin—breast cancer	3.61e-05	0.000147	CcSEcCtD
Tadalafil—Dermatitis—Capecitabine—breast cancer	3.61e-05	0.000147	CcSEcCtD
Tadalafil—Tachycardia—Doxorubicin—breast cancer	3.61e-05	0.000146	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—CYP17A1—breast cancer	3.59e-05	0.000343	CbGpPWpGaD
Tadalafil—Headache—Capecitabine—breast cancer	3.59e-05	0.000146	CcSEcCtD
Tadalafil—Skin disorder—Doxorubicin—breast cancer	3.59e-05	0.000146	CcSEcCtD
Tadalafil—Paraesthesia—Epirubicin—breast cancer	3.59e-05	0.000146	CcSEcCtD
Tadalafil—Hyperhidrosis—Doxorubicin—breast cancer	3.57e-05	0.000145	CcSEcCtD
Tadalafil—Dyspnoea—Epirubicin—breast cancer	3.56e-05	0.000145	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—PTGS1—breast cancer	3.56e-05	0.000339	CbGpPWpGaD
Tadalafil—Somnolence—Epirubicin—breast cancer	3.55e-05	0.000144	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP17A1—breast cancer	3.54e-05	0.000338	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FGFR1—breast cancer	3.54e-05	0.000337	CbGpPWpGaD
Tadalafil—Nausea—Docetaxel—breast cancer	3.52e-05	0.000143	CcSEcCtD
Tadalafil—Dyspepsia—Epirubicin—breast cancer	3.52e-05	0.000143	CcSEcCtD
Tadalafil—Gastrointestinal pain—Methotrexate—breast cancer	3.49e-05	0.000142	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—CYP2D6—breast cancer	3.49e-05	0.000333	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—HRAS—breast cancer	3.49e-05	0.000333	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HIF1A—breast cancer	3.48e-05	0.000332	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—AKT1—breast cancer	3.46e-05	0.000329	CbGpPWpGaD
Tadalafil—Hypotension—Doxorubicin—breast cancer	3.45e-05	0.00014	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Epirubicin—breast cancer	3.45e-05	0.00014	CcSEcCtD
Tadalafil—Fatigue—Epirubicin—breast cancer	3.44e-05	0.00014	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP2D6—breast cancer	3.44e-05	0.000328	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—NCOA2—breast cancer	3.42e-05	0.000326	CbGpPWpGaD
Tadalafil—Constipation—Epirubicin—breast cancer	3.41e-05	0.000139	CcSEcCtD
Tadalafil—Pain—Epirubicin—breast cancer	3.41e-05	0.000139	CcSEcCtD
Tadalafil—Nausea—Capecitabine—breast cancer	3.4e-05	0.000138	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—LEP—breast cancer	3.4e-05	0.000324	CbGpPWpGaD
Tadalafil—Urticaria—Methotrexate—breast cancer	3.39e-05	0.000138	CcSEcCtD
Tadalafil—Abdominal pain—Methotrexate—breast cancer	3.37e-05	0.000137	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CAV1—breast cancer	3.37e-05	0.000321	CbGpPWpGaD
Tadalafil—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.37e-05	0.000137	CcSEcCtD
Tadalafil—Insomnia—Doxorubicin—breast cancer	3.34e-05	0.000136	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—KDR—breast cancer	3.33e-05	0.000318	CbGpPWpGaD
Tadalafil—Paraesthesia—Doxorubicin—breast cancer	3.32e-05	0.000135	CcSEcCtD
Tadalafil—Dyspnoea—Doxorubicin—breast cancer	3.29e-05	0.000134	CcSEcCtD
Tadalafil—Somnolence—Doxorubicin—breast cancer	3.28e-05	0.000133	CcSEcCtD
Tadalafil—Gastrointestinal pain—Epirubicin—breast cancer	3.27e-05	0.000133	CcSEcCtD
Tadalafil—Dyspepsia—Doxorubicin—breast cancer	3.25e-05	0.000132	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ESR1—breast cancer	3.25e-05	0.00031	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FN1—breast cancer	3.21e-05	0.000306	CbGpPWpGaD
Tadalafil—Gastrointestinal disorder—Doxorubicin—breast cancer	3.19e-05	0.00013	CcSEcCtD
Tadalafil—Fatigue—Doxorubicin—breast cancer	3.19e-05	0.000129	CcSEcCtD
Tadalafil—Urticaria—Epirubicin—breast cancer	3.17e-05	0.000129	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—NFKBIA—breast cancer	3.17e-05	0.000302	CbGpPWpGaD
Tadalafil—Constipation—Doxorubicin—breast cancer	3.16e-05	0.000128	CcSEcCtD
Tadalafil—Pain—Doxorubicin—breast cancer	3.16e-05	0.000128	CcSEcCtD
Tadalafil—Abdominal pain—Epirubicin—breast cancer	3.16e-05	0.000128	CcSEcCtD
Tadalafil—Hypersensitivity—Methotrexate—breast cancer	3.14e-05	0.000128	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—NOTCH1—breast cancer	3.14e-05	0.000299	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—AKT1—breast cancer	3.08e-05	0.000294	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—KIT—breast cancer	3.07e-05	0.000293	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—APC—breast cancer	3.07e-05	0.000293	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CG—breast cancer	3.07e-05	0.000293	CbGpPWpGaD
Tadalafil—Asthenia—Methotrexate—breast cancer	3.06e-05	0.000124	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—EGF—breast cancer	3.03e-05	0.000289	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP1B1—breast cancer	3.02e-05	0.000288	CbGpPWpGaD
Tadalafil—Gastrointestinal pain—Doxorubicin—breast cancer	3.02e-05	0.000123	CcSEcCtD
Tadalafil—Pruritus—Methotrexate—breast cancer	3.02e-05	0.000123	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP1B1—breast cancer	2.98e-05	0.000284	CbGpPWpGaD
Tadalafil—Hypersensitivity—Epirubicin—breast cancer	2.94e-05	0.000119	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—MAPK3—breast cancer	2.94e-05	0.00028	CbGpPWpGaD
Tadalafil—Urticaria—Doxorubicin—breast cancer	2.94e-05	0.000119	CcSEcCtD
Tadalafil—Abdominal pain—Doxorubicin—breast cancer	2.92e-05	0.000119	CcSEcCtD
Tadalafil—Diarrhoea—Methotrexate—breast cancer	2.92e-05	0.000119	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—BRAF—breast cancer	2.89e-05	0.000275	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—NCOA1—breast cancer	2.89e-05	0.000275	CbGpPWpGaD
Tadalafil—Asthenia—Epirubicin—breast cancer	2.87e-05	0.000116	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—CYP19A1—breast cancer	2.84e-05	0.000271	CbGpPWpGaD
Tadalafil—Pruritus—Epirubicin—breast cancer	2.83e-05	0.000115	CcSEcCtD
Tadalafil—Dizziness—Methotrexate—breast cancer	2.82e-05	0.000115	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—IGF1—breast cancer	2.81e-05	0.000268	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AKT2—breast cancer	2.81e-05	0.000268	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP19A1—breast cancer	2.8e-05	0.000267	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—EGFR—breast cancer	2.8e-05	0.000267	CbGpPWpGaD
Tadalafil—Diarrhoea—Epirubicin—breast cancer	2.73e-05	0.000111	CcSEcCtD
Tadalafil—Hypersensitivity—Doxorubicin—breast cancer	2.72e-05	0.000111	CcSEcCtD
Tadalafil—Vomiting—Methotrexate—breast cancer	2.71e-05	0.00011	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PIK3CD—breast cancer	2.7e-05	0.000257	CbGpPWpGaD
Tadalafil—Rash—Methotrexate—breast cancer	2.69e-05	0.000109	CcSEcCtD
Tadalafil—Dermatitis—Methotrexate—breast cancer	2.69e-05	0.000109	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CA—breast cancer	2.67e-05	0.000255	CbGpPWpGaD
Tadalafil—Headache—Methotrexate—breast cancer	2.67e-05	0.000109	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—SERPINE1—breast cancer	2.67e-05	0.000254	CbGpPWpGaD
Tadalafil—Asthenia—Doxorubicin—breast cancer	2.65e-05	0.000108	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—COMT—breast cancer	2.64e-05	0.000252	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—KRAS—breast cancer	2.64e-05	0.000252	CbGpPWpGaD
Tadalafil—Dizziness—Epirubicin—breast cancer	2.64e-05	0.000107	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—GSTP1—breast cancer	2.63e-05	0.000251	CbGpPWpGaD
Tadalafil—Pruritus—Doxorubicin—breast cancer	2.61e-05	0.000106	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—COMT—breast cancer	2.61e-05	0.000249	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTP1—breast cancer	2.6e-05	0.000247	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NOS3—breast cancer	2.55e-05	0.000243	CbGpPWpGaD
Tadalafil—Vomiting—Epirubicin—breast cancer	2.54e-05	0.000103	CcSEcCtD
Tadalafil—Nausea—Methotrexate—breast cancer	2.53e-05	0.000103	CcSEcCtD
Tadalafil—Diarrhoea—Doxorubicin—breast cancer	2.53e-05	0.000103	CcSEcCtD
Tadalafil—Rash—Epirubicin—breast cancer	2.52e-05	0.000102	CcSEcCtD
Tadalafil—Dermatitis—Epirubicin—breast cancer	2.52e-05	0.000102	CcSEcCtD
Tadalafil—Headache—Epirubicin—breast cancer	2.5e-05	0.000102	CcSEcCtD
Tadalafil—Dizziness—Doxorubicin—breast cancer	2.44e-05	9.92e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CA—breast cancer	2.43e-05	0.000231	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTM1—breast cancer	2.42e-05	0.00023	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MDM2—breast cancer	2.42e-05	0.00023	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—RAF1—breast cancer	2.41e-05	0.00023	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—RELA—breast cancer	2.4e-05	0.000229	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTM1—breast cancer	2.38e-05	0.000227	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ERBB2—breast cancer	2.38e-05	0.000227	CbGpPWpGaD
Tadalafil—Nausea—Epirubicin—breast cancer	2.37e-05	9.63e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—MTOR—breast cancer	2.35e-05	0.000224	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CB—breast cancer	2.35e-05	0.000224	CbGpPWpGaD
Tadalafil—Vomiting—Doxorubicin—breast cancer	2.35e-05	9.54e-05	CcSEcCtD
Tadalafil—Rash—Doxorubicin—breast cancer	2.33e-05	9.46e-05	CcSEcCtD
Tadalafil—Dermatitis—Doxorubicin—breast cancer	2.33e-05	9.45e-05	CcSEcCtD
Tadalafil—Headache—Doxorubicin—breast cancer	2.31e-05	9.4e-05	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—CYP1A1—breast cancer	2.29e-05	0.000219	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP1A1—breast cancer	2.26e-05	0.000216	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CXCL8—breast cancer	2.26e-05	0.000216	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—HRAS—breast cancer	2.25e-05	0.000214	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CDKN1B—breast cancer	2.21e-05	0.00021	CbGpPWpGaD
Tadalafil—Nausea—Doxorubicin—breast cancer	2.19e-05	8.91e-05	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—AKT1—breast cancer	2.18e-05	0.000208	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CASP3—breast cancer	2.16e-05	0.000206	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IL2—breast cancer	2.16e-05	0.000206	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—IL6—breast cancer	2.15e-05	0.000205	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CCND1—breast cancer	2.11e-05	0.000201	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—JUN—breast cancer	2.1e-05	0.0002	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CTNNB1—breast cancer	2.09e-05	0.000199	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MMP9—breast cancer	2.04e-05	0.000195	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CDKN1A—breast cancer	2.04e-05	0.000194	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PTEN—breast cancer	2.03e-05	0.000194	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MAPK8—breast cancer	1.99e-05	0.00019	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—AKT1—breast cancer	1.98e-05	0.000189	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SRC—breast cancer	1.89e-05	0.00018	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SYNJ2—breast cancer	1.84e-05	0.000176	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—VEGFA—breast cancer	1.84e-05	0.000175	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—STAT3—breast cancer	1.82e-05	0.000173	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MAPK3—breast cancer	1.74e-05	0.000166	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NDUFS3—breast cancer	1.71e-05	0.000163	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MYC—breast cancer	1.69e-05	0.000161	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TGFB1—breast cancer	1.69e-05	0.000161	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—EGFR—breast cancer	1.65e-05	0.000158	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CHST9—breast cancer	1.61e-05	0.000154	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—KRAS—breast cancer	1.56e-05	0.000149	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—COX11—breast cancer	1.53e-05	0.000146	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CA—breast cancer	1.43e-05	0.000137	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CDA—breast cancer	1.4e-05	0.000133	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SHMT1—breast cancer	1.4e-05	0.000133	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TP53—breast cancer	1.39e-05	0.000132	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLCO1B1—breast cancer	1.35e-05	0.000128	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC2A5—breast cancer	1.35e-05	0.000128	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HRAS—breast cancer	1.33e-05	0.000126	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—APRT—breast cancer	1.3e-05	0.000124	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IL6—breast cancer	1.27e-05	0.000121	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ANGPTL4—breast cancer	1.22e-05	0.000116	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ESRRA—breast cancer	1.22e-05	0.000116	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AKT1—breast cancer	1.17e-05	0.000112	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HADHB—breast cancer	1.16e-05	0.00011	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GPI—breast cancer	1.16e-05	0.00011	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ALDH7A1—breast cancer	1.1e-05	0.000105	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ALDH1A1—breast cancer	1.1e-05	0.000105	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NME1—breast cancer	1.06e-05	0.000101	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—UMPS—breast cancer	1.06e-05	0.000101	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—FHL2—breast cancer	1.06e-05	0.000101	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ADSL—breast cancer	1.06e-05	0.000101	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PHGDH—breast cancer	1.06e-05	0.000101	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—BRIP1—breast cancer	1.04e-05	9.9e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HPSE—breast cancer	1.04e-05	9.9e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—LDHB—breast cancer	1.04e-05	9.9e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTA3—breast cancer	9.85e-06	9.39e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ABCC1—breast cancer	9.85e-06	9.39e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HMMR—breast cancer	9.85e-06	9.39e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PPARGC1B—breast cancer	9.54e-06	9.09e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CA9—breast cancer	9.01e-06	8.58e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTA4—breast cancer	9.01e-06	8.58e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTA2—breast cancer	8.78e-06	8.37e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GPX2—breast cancer	8.78e-06	8.37e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SULT1A1—breast cancer	8.67e-06	8.26e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GPX4—breast cancer	8.67e-06	8.26e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—IDH1—breast cancer	8.47e-06	8.07e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTA1—breast cancer	8.47e-06	8.07e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NAT2—breast cancer	8.37e-06	7.98e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MED12—breast cancer	7.34e-06	7e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—DPYD—breast cancer	7.34e-06	7e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ALDOA—breast cancer	7.23e-06	6.89e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NCOA3—breast cancer	7.02e-06	6.69e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC2A2—breast cancer	6.97e-06	6.64e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ABCG2—breast cancer	6.83e-06	6.51e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MTR—breast cancer	6.83e-06	6.51e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CPT1A—breast cancer	6.83e-06	6.51e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HPGDS—breast cancer	6.69e-06	6.38e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HBA1—breast cancer	6.65e-06	6.34e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ACHE—breast cancer	6.49e-06	6.19e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTT1—breast cancer	6.49e-06	6.19e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP17A1—breast cancer	6.15e-06	5.86e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ENO1—breast cancer	6.08e-06	5.8e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PTGS1—breast cancer	6.08e-06	5.8e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP2D6—breast cancer	5.97e-06	5.69e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NCOA2—breast cancer	5.86e-06	5.58e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—FASN—breast cancer	5.68e-06	5.41e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—BCHE—breast cancer	5.66e-06	5.39e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC5A5—breast cancer	5.59e-06	5.33e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC2A1—breast cancer	5.4e-06	5.14e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NQO1—breast cancer	5.4e-06	5.14e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP1B1—breast cancer	5.17e-06	4.93e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HSP90AA1—breast cancer	5.07e-06	4.84e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NCOA1—breast cancer	4.93e-06	4.7e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—STK11—breast cancer	4.86e-06	4.64e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP19A1—breast cancer	4.86e-06	4.64e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—COMT—breast cancer	4.52e-06	4.31e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTP1—breast cancer	4.5e-06	4.29e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HMOX1—breast cancer	4.44e-06	4.23e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ITPR1—breast cancer	4.43e-06	4.22e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ABCB1—breast cancer	4.26e-06	4.06e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—TYMS—breast cancer	4.18e-06	3.99e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTM1—breast cancer	4.14e-06	3.94e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PLA2G4A—breast cancer	4.14e-06	3.94e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NCOR1—breast cancer	4.14e-06	3.94e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GPX1—breast cancer	3.96e-06	3.77e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP1A1—breast cancer	3.92e-06	3.74e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ERCC2—breast cancer	3.89e-06	3.71e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MTHFR—breast cancer	3.65e-06	3.48e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CAV1—breast cancer	3.37e-06	3.21e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CG—breast cancer	3.07e-06	2.93e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CD—breast cancer	2.7e-06	2.57e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ALB—breast cancer	2.66e-06	2.54e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NOS3—breast cancer	2.55e-06	2.43e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CB—breast cancer	2.35e-06	2.24e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PTGS2—breast cancer	2.33e-06	2.22e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PTEN—breast cancer	2.03e-06	1.94e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CA—breast cancer	1.43e-06	1.37e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AKT1—breast cancer	1.17e-06	1.12e-05	CbGpPWpGaD
